Karen E Andersen from Metairie, LA, age 63

Professional Records

Lawyers & Attorneys

Karen Andersen - Lawyer

View page

Specialties:

Elder Law
Family
Real Estate
School Law
Wills-Trusts-Probate
Wills-Trusts-Probate

ISLN:

924434738

Admitted:

2013

Law School:

Albany Law School, J.D., 2009

License Records

Karen L Andersen

License #:

22363 - Expired

Category:

Cosmetology

Issued Date:

Aug 1, 1968

Effective Date:

Mar 1, 1995

Type:

Cosmetologist

Karen J Andersen

License #:

14198 - Expired

Category:

Emergency Medical Care

Issued Date:

Dec 20, 2000

Effective Date:

Feb 6, 2004

Expiration Date:

Dec 31, 2003

Type:

EMT

Resumes

Karen Andersen

View page

Location:

United States

Manager/Ceo At Postal Family Fcu

View page

Position:

Manager/CEO at Postal Family FCU

Location:

Fargo, North Dakota

Industry:

Banking

Work:

Postal Family FCU - Fargo, North Dakota Area since Feb 1999
Manager/CEO
Fargo Public Schools Federal Credit Union - Fargo, North Dakota Area Jun 1981 - Feb 1999
Loan Manager

Education:

Minnesota State University, Moorhead 1977 - 1981
BA, Criminal Justice, Sociology

Karen Andersen

View page

Location:

United States

Karen Andersen

View page

Location:

United States

Karen Andersen

View page

Location:

United States

Karen Andersen

View page

Location:

United States

Business Records

Name / Title

Company / Classification

Phones & Addresses

Karen Andersen
Partner

All Things Organic
Garden & Lawn Equipment & Supplies. Internet Selling Services. Garden Centres

3896 201 a St, Langley, BC V3A 1R2
(604) 533-1448, (604) 533-1448

Karen Andersen
Partner

All Things Organic
Garden & Lawn Equipment & Supplies · Internet Selling Services · Garden Centres

(604) 533-1448, (604) 533-1448

News

COVID-19 vaccine boosters could mean billions for drugmakers

View page

No one knows yet how many people will get the extra shots. But Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in global sales next year for Pfizer and BioNTech and around $14 billion for Moderna if they are endorsed for nearly all Americans.

Date

Sep 25, 2021

Category:

More news

Source:

Google

Roche sees Perjeta addition boost its breast cancer combo

View page

The Basel, Switzerland-based company's pricing power in the HER2-positive breast cancer market is strengthened by the Aphinity data, Morningstar analyst Karen Andersen wrote, adding that the company "is likely to bundle these therapies, particularly now that the combination has shown superior data a

Date

Mar 02, 2017

Category:

Health

Source:

Google

Biogen shedding blood

View page

Morningstar analyst Karen Andersen said the deal adds weight to speculation that Biogen could be an acquisition target. Potential buyers of its core neuro franchise wont be put off by concerns about long-term competitive threats in hemophilia, she said, citing Switzerlands Roche as one likely su

Date

May 04, 2016

Category:

Business

Source:

Google

FDA accepts Novo Nordisk's resubmitted application for insulin drug

View page

Tresiba also gives Novo an important foundation for future combination regimens in the United States, which accounts for slightly more than half of a $23 billion global diabetes market, Morningstar's Karen Andersen said in note in March.

Date

Apr 07, 2015

Category:

Health

Source:

Google

InterMune drug may offer big upside to Roche if aimed at liver

View page

"It's not something we've included in our valuation" of InterMune, said Morningstar analyst Karen Andersen, given the many failures of other drugs that have attempted to treat liver fibrosis, and InterMune's focus on preparing for the U.S. launch of pirfenidone.

Date

Aug 27, 2014

Category:

Health

Source:

Google

FDA panel rejects Avastin for breast cancer use

View page

"Avastin has sales in breast cancer in other markets and for many other indications, (so) this really does not have a significant impact on our evaluation of Roche overall," said Karen Andersen, an analyst at Morningstar.

Date

Jun 29, 2011

Category:

Health

Source:

Google

US to hear Roche on Avastin for breast cancer

View page

Medicare, the U.S. federal health insurer, is likely to cut coverage for Avastin in breast cancer if the FDA revokes that use. That could shrink U.S. sales by half in 2011 to $400 million, said Karen Andersen, analyst at Morningstar.

Date

Jun 28, 2011

Category:

Health

Source:

Google

Roche to fight for Avastin as breast cancer drug

View page

"Roche has been searching for years for the right biomarker. At this point, it would be an unexpected outcome if the FDA decided to preserve the label while they're waiting for that data," said Morningstar analyst Karen Andersen.

Date

Jun 26, 2011

Category:

Health

Source:

Google

Publications